The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes

Bekpınar, Seldağ; Yenidünya, Gülşah; Gürdöl, Figen; Ünlüçerçi, Yeşim; Aycan-Ustyol, Esra; Dınççağ, Nevin

doi:10.1016/j.clinbiochem.2015.08.001

Cited by 17 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of apoM and S1P in the development of DN has only been addressed in a limited number of studies, but with various outcomes dependent on study design, size, and primary aim. In a study on T2D, individuals were segregated based on the degree of albuminuria (31). The plasma S1P levels declined with kidney function, as explained by the loss of albumin in urine.…”

Section: Can Apom/s1p Contribute To the Diagnosis Of Diabetic Nephropathy (Dn)?mentioning

confidence: 99%

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Christoffersen

2021

Front. Endocrinol.

View full text Add to dashboard Cite

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.

show abstract

Section: Can Apom/s1p Contribute To the Diagnosis Of Diabetic Nephropathy (Dn)?mentioning

confidence: 99%

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Christoffersen

2021

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Changes in plasma S1P levels could be a result of excess loss via the urine. In support of this idea, results from a study in patients with T2D showed an inverse association between urinary albumin excretion and plasma S1P levels (89). In another study, albuminuria in patients with IgA nephropathy was found to have a positive correlation with both serum S1P and urinary S1P levels (100).…”

Section: Association Of Apom and S1p Levels With Kidney Function In Kidney Diseasementioning

confidence: 85%

The apoM/S1P Complex—A Mediator in Kidney Biology and Disease?

Bisgaard

Christoffersen

2021

Front. Med.

View full text Add to dashboard Cite

Kidney disease affects more than 10% of the population, can be both acute and chronic, and is linked to other diseases such as cardiovascular disease, diabetes, and sepsis. Despite the detrimental consequences for patients, no good treatment options directly targeting the kidney are available. Thus, a better understanding of the pathology and new treatment modalities are required. Accumulating evidence suggests that the apolipoprotein M/sphingosine−1-phosphate (apoM/S1P) axis is a likely drug target, but significant gaps in our knowledge remain. In this review, we present what has so far been elucidated about the role of apoM in normal kidney biology and describe how changes in the apoM/S1P axis are thought to affect the development of kidney disease. ApoM is primarily produced in the liver and kidneys. From the liver, apoM is secreted into circulation, where it is attached to lipoproteins (primarily HDL). Importantly, apoM is a carrier of the bioactive lipid S1P. S1P acts by binding to five different receptors. Together, apoM/S1P plays a role in several biological mechanisms, such as inflammation, endothelial cell permeability, and lipid turnover. In the kidney, apoM is primarily expressed in the proximal tubular cells. S1P can be produced locally in the kidney, and several of the five S1P receptors are present in the kidney. The functional role of kidney-derived apoM as well as plasma-derived apoM is far from elucidated and will be discussed based on both experimental and clinical studies. In summary, the current studies provide evidence that support a role for the apoM/S1P axis in kidney disease; however, additional pre-clinical and clinical studies are needed to reveal the mechanisms and target potential in the treatment of patients.

show abstract

“…A total of 10 works [7, 11, 12, 16–22] that matched the research criteria of the study design were adopted. Among them, five were case-control studies [7, 11, 16, 17, 21] and five were cross-sectional studies [12, 18–20, 22], including 942 DM with retinopathy, neuropathy, and nephropathy and 873 controls. The basic characteristics of the studies involved are displayed in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis

Liu

Chen

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Objective. The purpose of the meta-analysis was to evaluate the relationship between serum asymmetric dimethylarginine (ADMA) level and microvascular complications in diabetes mellitus (DM) including diabetic retinopathy (DR), diabetic neuropathy (DN), and diabetic nephropathy. Methods. Studies were comprehensively identified by searching Web of Science, Embase, and PubMed databases up to August 30, 2018. The meta-analysis was carried out to compare the difference of serum ADMA concentrations of DR, DN, and diabetic nephropathy patients with healthy controls. The Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality were applied to assess the methodological quality. Chi-squared Q test and I2 statistics were applied to evaluate statistical heterogeneity. Subgroup analyses were conducted and publication bias was assessed by Egger’s test. Result. Ten studies were finally entered in the meta-analysis. Statistically significant heterogeneity was observed across these studies (I2 = 77.0%, p < 0.001). Compared with DM without microvascular complications, circulating level of ADMA was significantly higher in DM with microvascular complications (all p < 0.05). Sensitivity analysis suggested that the results of this meta-analysis were shown to be stable. There was no significant publication bias (P=0.823). Conclusion. Elevated ADMA levels correlate with diabetic microangiopathies such as DR and diabetic nephropathy. ADMA may play an important role in the pathobiology of microvascular complications of diabetes.

show abstract

The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes

Cited by 17 publications

References 32 publications

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

The apoM/S1P Complex—A Mediator in Kidney Biology and Disease?

Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis

Contact Info

Product

Resources

About